Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 3:32 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 433–456 of 1,199 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: RAYOS Clear all
Completed Phase 2 Interventional

Combination Chemotherapy in Treating Children With Very High Risk Acute Lymphocytic Leukemia

NCT00003783
View directory record Official record
Conditions
Leukemia
Interventions
filgrastim, asparaginase, cyclophosphamide, cytarabine, daunorubicin hydrochloride, dexamethasone, etoposide, idarubicin, leucovorin calcium, mercaptopurine, methotrexate, prednisone, vincristine sulfate, radiation therapy
Biological · Drug · Radiation
Lead sponsor
Children's Oncology Group
Network
Eligibility
Up to 17 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2007
U.S. locations
51
States / cities
Tucson, Arizona • Palo Alto, California • Sacramento, California + 44 more
Source: ClinicalTrials.gov public record
Updated Jul 28, 2014 · Synced Oct 23, 2026, 3:32 PM EDT
Terminated Phase 3 Interventional Results available

Sunitinib Plus Prednisone In Patients With Metastatic Castration-Resistant Prostate Cancer After Failure Of Docetaxel Chemotherapy

NCT00676650
View directory record Official record
Conditions
Prostatic Neoplasms
Interventions
Prednisone, sunitinib, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older · Male only
Enrollment
873 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
87
States / cities
Decatur, Alabama • Huntsville, Alabama • Anaheim, California + 73 more
Source: ClinicalTrials.gov public record
Updated Mar 8, 2013 · Synced Oct 23, 2026, 3:32 PM EDT
Completed Phase 2 Interventional Results available

S0313 Cyclophosphamide, Doxorubicin, Vincristine, Prednisone, and Radiation Therapy Followed By Rituximab and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Stage I or Stage II Non-Hodgkin's Lymphoma

NCT00070018
View directory record Official record
Conditions
Lymphoma
Interventions
rituximab, Cyclophosphamide, doxorubicin hydrochloride, prednisone, vincristine sulfate, radiation therapy, Yttrium-90 ibritumomab tiuxetan, Indium-111 ibritumomab tiuxetan
Biological · Drug · Radiation
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2015
U.S. locations
48
States / cities
Anchorage, Alaska • Burbank, California • Boise, Idaho + 33 more
Source: ClinicalTrials.gov public record
Updated Jan 11, 2022 · Synced Oct 23, 2026, 3:32 PM EDT
Active, not recruiting Phase 2 Interventional

Combination Chemotherapy and Ponatinib Hydrochloride in Treating Patients With Acute Lymphoblastic Leukemia

NCT01424982
View directory record Official record
Conditions
Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Lymphoblastic Leukemia, Adult Acute Lymphoblastic Leukemia in Complete Remission, B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1, Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Philadelphia Chromosome Positive, Untreated Adult Acute Lymphoblastic Leukemia
Interventions
Cyclophosphamide, Cytarabine, Dexamethasone, Doxorubicin, Doxorubicin Hydrochloride, Laboratory Biomarker Analysis, Methotrexate, Ponatinib, Ponatinib Hydrochloride, Prednisone, Rituximab, Vincristine, Vincristine Sulfate
Drug · Other · Biological
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 23, 2026, 3:32 PM EDT
Completed Not applicable Interventional

Cell Biology of Steroid Resistant Asthma

NCT00361920
View directory record Official record
Conditions
Asthma
Interventions
prednisone
Drug
Lead sponsor
National Jewish Health
Other
Eligibility
12 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Mar 29, 2017 · Synced Oct 23, 2026, 3:32 PM EDT
Completed Phase 1 Interventional

A Study of Cetrelimab (JNJ-63723283), a Programmed Cell Death Receptor-1 (PD-1) Inhibitor, Administered in Combination With Apalutamide in Participants With Metastatic Castration-Resistant Prostate Cancer

NCT03551782
View directory record Official record
Conditions
Castration-Resistant Prostatic Neoplasms
Interventions
Cetrelimab 480 mg, Apalutamide 240 mg
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older · Male only
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
11
States / cities
San Francisco, California • Shreveport, Louisiana • Ann Arbor, Michigan + 7 more
Source: ClinicalTrials.gov public record
Updated Feb 25, 2022 · Synced Oct 23, 2026, 3:32 PM EDT
Completed Phase 2 Interventional Results available

Bevacizumab and Combination Chemotherapy in Treating Patients With Peripheral T-Cell Lymphoma or Natural Killer Cell Neoplasms

NCT00217425
View directory record Official record
Conditions
Lymphoma
Interventions
bevacizumab, cyclophosphamide, doxorubicin, prednisone, vincristine
Biological · Drug
Lead sponsor
Eastern Cooperative Oncology Group
Network
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2014
U.S. locations
110
States / cities
Greenbrae, California • Palo Alto, California • Fort Collins, Colorado + 77 more
Source: ClinicalTrials.gov public record
Updated Jun 18, 2023 · Synced Oct 23, 2026, 3:32 PM EDT
Completed Phase 3 Interventional Results available

BBR 2778 for Relapsed, Aggressive Non-Hodgkin's Lymphoma (NHL)

NCT00088530
View directory record Official record
Conditions
Lymphoma, Non-Hodgkin
Interventions
pixantrone, cyclophosphamide, vincristine, rituximab, prednisone, Vinorelbine, Oxalplatin, Ifosfasmide, Etoposide, Mitoxatrone, Gemcitabine or Rituximab
Drug
Lead sponsor
CTI BioPharma
Industry
Eligibility
18 Years and older
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2010
U.S. locations
9
States / cities
Fountain Valley, California • Los Angeles, California • Lakeland, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Feb 5, 2020 · Synced Oct 23, 2026, 3:32 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Higher Dose of Rituxan Versus Standard Doses of Rituxan With Cyclophosphamide, Vincristine, and Prednisone in Subjects With Chronic ITP

NCT00774202
View directory record Official record
Conditions
Immune Thrombocytopenic Purpura
Interventions
Rituxan, Cyclophosphamide, Vincristine, Prednisone, Higher Dose of Rituximab
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
12 Years to 100 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 9, 2019 · Synced Oct 23, 2026, 3:32 PM EDT
Completed Phase 4 Interventional Results available

Steroid Treatment for Hypereosinophilic Syndrome

NCT01524536
View directory record Official record
Conditions
Eosinophilia, Hypereosinophilic Syndrome, Leukocyte Disorder, Hematologic Diseases
Interventions
prednisone
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
7 Years to 100 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2020
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 15, 2022 · Synced Oct 23, 2026, 3:32 PM EDT
Completed Phase 2 Interventional

A Study Comparing AT-101 in Combination With Docetaxel and Prednisone Versus Docetaxel and Prednisone in Men With Chemotherapy-Naïve Metastatic Hormone Refractory Prostate Cancer (HRPC)

NCT00571675
View directory record Official record
Conditions
Hormone Refractory Prostate Cancer
Interventions
AT-101, prednisone and docetaxel, placebo, prednisone and docetaxel
Drug
Lead sponsor
Ascenta Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
24
States / cities
Colorado Springs, Colorado • New Port Richey, Florida • Ocoee, Florida + 21 more
Source: ClinicalTrials.gov public record
Updated Nov 9, 2010 · Synced Oct 23, 2026, 3:32 PM EDT
Completed Phase 2 Interventional Results available

Phase II Trial of Alemtuzumab (Campath) and Dose-Adjusted EPOCH-Rituximab (DA-EPOCH-R) in Relapsed or Refractory Diffuse Large B-Cell and Hodgkin Lymphomas

NCT01030900
View directory record Official record
Conditions
Hodgkin Lymphoma, Diffuse Large B-Cell Lymphoma
Interventions
Campath, Rituximab, EPOCH
Biological · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2021
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 6, 2022 · Synced Oct 23, 2026, 3:32 PM EDT
Completed Phase 2 Interventional

Combination Chemotherapy and Monoclonal Antibody Therapy in Treating Patients With Non-Hodgkin's Lymphoma

NCT00032019
View directory record Official record
Conditions
Lymphoma
Interventions
filgrastim, rituximab, cyclophosphamide, doxorubicin hydrochloride, etoposide, prednisone, vincristine sulfate
Biological · Drug
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
Not listed
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2009
U.S. locations
80
States / cities
Anniston, Alabama • La Jolla, California • Los Angeles, California + 60 more
Source: ClinicalTrials.gov public record
Updated Jul 19, 2016 · Synced Oct 23, 2026, 3:32 PM EDT
Completed Phase 2 Interventional Results available

Rituximab, Chemotherapy, and Filgrastim in Treating Patients With Burkitt's Lymphoma or Burkitt's Leukemia

NCT00039130
View directory record Official record
Conditions
Leukemia, Lymphoma
Interventions
filgrastim, rituximab, cyclophosphamide, cytarabine, dexamethasone, doxorubicin hydrochloride, etoposide, ifosfamide, leucovorin calcium, methotrexate, prednisone, vincristine sulfate, Allopurinol
Biological · Drug
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
16 Years and older
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2014
U.S. locations
31
States / cities
San Diego, California • Lewes, Delaware • Newark, Delaware + 25 more
Source: ClinicalTrials.gov public record
Updated Aug 21, 2023 · Synced Oct 23, 2026, 3:32 PM EDT
Terminated Phase 3 Interventional Results available

Study Comparing Inotuzumab Ozogamicin In Combination With Rituximab Versus Defined Investigator's Choice In Follicular Non-Hodgkin's Lymphoma (NHL)

NCT00562965
View directory record Official record
Conditions
Lymphoma, Follicular
Interventions
inotuzumab ozogamicin, rituximab, cyclophosphamide, vincristine, prednisone/prednisolone, mitoxantrone, fludarabine, dexamethasone
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
17
States / cities
Mission Hills, California • Evansville, Indiana • Baltimore, Maryland + 13 more
Source: ClinicalTrials.gov public record
Updated Jan 9, 2018 · Synced Oct 23, 2026, 3:32 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Study Of SU011248 In Combination With Docetaxel (Taxotere) And Prednisone In Patients With Prostate Cancer

NCT00137436
View directory record Official record
Conditions
Prostatic Neoplasms
Interventions
Docetaxel, Prednisone, SU011248
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older · Male only
Enrollment
93 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
24
States / cities
Harvey, Illinois • Tinley Park, Illinois • Hobart, Indiana + 17 more
Source: ClinicalTrials.gov public record
Updated Aug 29, 2011 · Synced Oct 23, 2026, 3:32 PM EDT
Terminated Phase 1 Interventional

Isatuximab, Bendamustine, and Prednisone in Refractory Multiple Myeloma

NCT04083898
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Isatuximab, Bendamustine, Prednisone
Biological · Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Mar 19, 2024 · Synced Oct 23, 2026, 3:32 PM EDT
Terminated Phase 4 Interventional Results available

Use of NPH Versus Basal Bolus Insulin for Steroid Induced Hyperglycemia

NCT03511521
View directory record Official record
Conditions
Hyperglycemia Steroid-induced, Insulin Resistance, Diabetes
Interventions
NPH Insulin, glargine, Insulin Aspart
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 11, 2020 · Synced Oct 23, 2026, 3:32 PM EDT
Recruiting Phase 1 Interventional

Phase IA and IB Study of AAVrh.10hFXN Gene Therapy for the Cardiomyopathy of Friedreich's Ataxia

NCT05302271
View directory record Official record
Conditions
Friedreich Ataxia, Cardiomyopathies, Cardiac Hypertrophy, Myocardial Fibrosis
Interventions
AAVrh.10hFXN, serotype rh.10 adeno-associated virus (AAV) gene transfer vector expressing the cDNA coding for human FXN, Prednisone
Biological · Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
12 Years to 50 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2029
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 23, 2026, 3:32 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Steroid-Free Versus Steroid-Based Immunosuppression in Pediatric Renal (Kidney) Transplantation

NCT00141037
View directory record Official record
Conditions
Kidney Diseases, Kidney Transplantation, Kidney Transplant, Renal Transplantation, Renal Transplant
Interventions
Daclizumab, Mycophenolate mofetil (MMF), Prednisone, Tacrolimus, Ganciclovir, Valganciclovir, Trimethoprim and sulfamethoxazole
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Up to 21 Years
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2010
U.S. locations
12
States / cities
Birmingham, Alabama • Los Angeles, California • Palo Alto, California + 8 more
Source: ClinicalTrials.gov public record
Updated Nov 29, 2016 · Synced Oct 23, 2026, 3:32 PM EDT
Recruiting Phase 3 Interventional

Cardiac Sarcoidosis Randomized Trial

NCT03593759
View directory record Official record
Conditions
Cardiac Sarcoidosis, Sarcoidosis
Interventions
Prednisone or Prednisolone, Methotrexate
Drug
Lead sponsor
Ottawa Heart Institute Research Corporation
Other
Eligibility
18 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
9
States / cities
New Haven, Connecticut • Boston, Massachusetts • Ann Arbor, Michigan + 6 more
Source: ClinicalTrials.gov public record
Updated Jul 10, 2026 · Synced Oct 23, 2026, 3:32 PM EDT
Completed Phase 2 Interventional Results available

Mitoxantrone ± Cetuximab 2nd Line Androgen Independent Prostate Cancer (AIPC)

NCT00661492
View directory record Official record
Conditions
Androgen-independent Prostate Cancer
Interventions
cetuximab, Mitoxantrone
Drug
Lead sponsor
US Oncology Research
Industry
Eligibility
18 Years and older · Male only
Enrollment
115 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
55
States / cities
Phoenix, Arizona • Sedona, Arizona • Denver, Colorado + 49 more
Source: ClinicalTrials.gov public record
Updated Dec 9, 2016 · Synced Oct 23, 2026, 3:32 PM EDT
Completed Phase 4 Interventional Results available

Acetaminophen (Tylenol) for Mood and Memory Changes Associated With Corticosteroid Therapy

NCT00377364
View directory record Official record
Conditions
Asthma, Rheumatic Disease
Interventions
Drug: Acetaminophen, Drug: Placebo
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated May 5, 2016 · Synced Oct 23, 2026, 3:32 PM EDT
Terminated Phase 4 Interventional Results available

Corticosteroids With Vedolizumab in Crohn's Disease

NCT02324699
View directory record Official record
Conditions
Crohn's Disease
Interventions
Prednisone, Placebo, Vedolizumab
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years to 70 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 26, 2019 · Synced Oct 23, 2026, 3:32 PM EDT